Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents in patients with type-2 diabetes. However, available data from clinical trials and meta-analyses suggest that SGLT2i have pleiotropic benefits in reducing mortality and delaying the pro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-04-01
|
| Series: | Kidney Diseases |
| Online Access: | https://www.karger.com/Article/FullText/530395 |